Overview of Protocol Deviations: Summary and Trends to Date

MTN Annual Meeting
ASPIRE Protocol Team Meeting
February 10, 2013



Introduction

- Review of PD reporting process
- Summary of ASPIRE PDs to date
- Trends
- Questions



PD Reporting Process

- Identify the PD
 - Prospectively
 - > Retrospectively
 - > Prior to occurrence
- Document the PD
 - Site staff
 - No stipulation on who must document it, as long as it is recorded in the participant's study record
 - What works best at the site
- Report the PD
 - Complete PD CRF Log



Reporting

Site awarene Deviation dat Has or will this						
	n:		dd	MMM yy		
3 Has or will thi	-		dd	мим уу]	
J. Has UI WIII UII	s deviation be reported to loc		yes no			
 Has or will this critical event? 	s deviation be reported to DA	IDS as a	yes no			
Type of devia	tion:	[dev	iation code (See back o	of form for code listin	g.)
Description of Plans and/or	deviation: action taken to address the de	wiation:				
B. Plans and/or	action taken to prevent future	occurrences of t	he deviation:			
Deviation report	rted by:	[staff code		


	Purpose: This form documents and reports protoco	-		
G	eneral Information/ Complete this form each time a protocol Instructions: (mtnregulatory@mtnstopshiv.org) and the as a deviation.		is identified. Consult the MTN Regulatory Team lanagement Team if you are unsure if an event requires report	
tem-spe	cific Instructions:			
	Page: Number pages sequentially for each part for deletion.	icipant, st	arting with 01. Do not re-assign page numbers if a form is man	
	item 2: Record the date the event occurred (star	date).		
	Item 5: Record the two-digit category code that be categories match. Describe the specifics		ibes the type of deviation. Use "99" (other) if none of the lister diation in Item 6.	
Code	Description	Code	Description	
01	Inappropriate enrollment: The participant enrolled and not all eligibility requirements were met.		Breach of confidentiality: Include potential and actual cases where participant confidentiality is breached. For example, a staff member puts a participant's name on a ca report form.	
02	92 Failure to follow trial randomization or blinding procedures: Include instances where randomization procedures were not followed by site staff, or product blinding procedures were not followed by pharmacy staff.			
			Physical assessment deviation: Include missed or incomplete physical/pelvic/rectal exam assessments.	
03	not instruct the participant to hold, permanently discontinue,		Lab assessment deviation: Include missed, or incomplet lab specimen collection.	
04	was dispensed to a participant, or study product was dispensed to a participant on product hold. Do not include any information related to study product assignment (product codes) on this form. Pharmacy staff must follow up with the MTN Pharmacist separately.		Mishandled lab specimen: Include errors in the labeling physical handling, processing, testing, storage, or shipme of collected lab specimens.	
			Staff performing duties that they are not qualified to perform: Use for any instance when any study procedure including clinical and darkinishtative procedures, is complet by a staff member who is not adequately qualified AND delegated to perform the procedure. Questionnaire administration deviation: A required questionnaire was not completed according to protocol requirements. Include instances where the wrong	
05				
06	Study product sharing: Participant has shared study product with another person or study participant.	18	questionnaire was completed.	
07	Study product not returned: Study product was not		Counseling deviation: Protocol-required counseling was not done and/or not documented correctly.	
80	administrative procedure was performed that was not		Use of non-IRB/EC-approved materials: Include use of ANY study-related material that requires IRB or EC approv for use per site requirements.	
standard of	specified in the protocol, and was not covered under local standard of care practice.	20	Use of excluded concomitant medications, devices or non-study products	
09	Improper AE/EAE follow-up: Use when an AE or EAE is not followed per protocol. For exemple, a clinical finding/lab result is not re-assessed as outlined in the protocol.	21	Informed consent process deviation: Examples include failure to accurately execute and/or document any part of thinformed consent process.	
10	Unreported AE: Site staff become aware of an AE, but do not report it per protocol requirements.		Visit completed outside of window: Use when visit procedures for a visit are done within the wrong window or	
11	Unreported EAE: Site staff become aware of an EAE, but do not report it per protocol and DAIDS EAE Manual		not in a designated visit window. For example, use if Visit 3: procedures are done in the Visit 4.0 window.	
	requirements.	99	Other	


Version 1.0, 14-NOV-12

NthiwelformsWTN_020/formslyr020_PDL.fm



ASPIRE PD Summary and Trends








- 377 PDs reported thus far
- Three most commonly reported PDs
 - 1. Mishandled Laboratory Sample Deviation 42%
 - 2. Study Product Use/Non Use Deviation 21%
 - 3. Physical Assessment Deviation 11%
- Constitute 75% of all reported PDs in ASPIRE
- 2 PDs (~ .5%)have been reported to DAIDS as potential Critical Events thus far







- FDA's "Most Commonly Cited PD's*" are:
 - Inappropriate enrollment (participant failed to meet eligibility criteria)
 - Physical assessment deviation (incomplete, incorrect, and/or missed assessment)
 - Laboratory evaluation deviation (incomplete, incorrect, missed evaluation and/or review of laboratory results/reports)
 - > Study product non-adherence



^{*} FDA site inspections occurring during 2008 and early 2009

Laboratory evaluation deviation

 Mishandled Laboratory Sample Deviation (42%)

Study product non-adherence


 Study Product Use/Non Use Deviation (21%)

Physical assessment deviation

 Physical Assessment Deviation (11%)



Breakdown of "Other" PDs n=32





Questions & Discussion





Thank you!

